Wedbush Morgan downgrades Amicus Therapeutics, Inc. (Nasdaq: FOLD) from Outperform to Underperform. Price target slashed from $17 to $3.50.

Wedbush ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE